L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe – Biotech Investments

Biophytis / Key word(s): Miscellaneous Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe 08-Aug-2023 / 07:00 CET/CEST

August 9, 2023

Female investors track progress, call for more women on boards and in leadership roles

A few years ago, when Beth Seidenberg searched for a biotech VC leader to help steer the next wave of investments at Westlake Village BioPartners,

March 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

L and J-HZ by L&J Bio for Herpes Zoster (Shingles): Likelihood of Approval

Biophytis receives a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe – Biotech Investments

Study reveals new mechanisms behind severe COVID-19 in obese individuals without diabetes

Female investors track progress, call for more women on boards and in leadership roles

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

Subscribe